Latest European Markets News

Little Green Pharma Ltd reported a 9.6% revenue increase to $19.2 million and slashed its net loss by 73% in the half-year ending September 2025, driven by strong growth in European medicinal cannabis markets.

James Hardie Industries reports a 34% jump in Q2 FY26 net sales driven by the AZEK acquisition and European growth, while grappling with margin pressures and integration costs.

ECS Botanics has successfully raised nearly A$2 million through a placement aimed at accelerating its international expansion and product development. The move underscores growing investor confidence in the medicinal cannabis company’s strategic growth plans.

Krakatoa Resources reports significant progress in drilling at its Zopkhito Antimony-Gold Project in Georgia, with most holes intersecting visible antimony mineralisation. Assay results are eagerly awaited to validate historical resource estimates and support a maiden JORC-compliant Mineral Resource.

Dyno Nobel Limited reported a robust 23% increase in EBIT for FY25, driven by strong explosives performance and transformation initiatives, while progressing its fertilisers separation and setting ambitious sustainability targets.

Memphasys Limited has successfully raised over $1.1 million through a pro-rata entitlement offer to accelerate the commercialisation of its innovative Felix™ sperm selection system, targeting key regulatory approvals and market expansion.

AVITA Medical reported a 13% drop in Q3 commercial revenue to $17.1 million but improved its net loss and secured CE Mark approval for RECELL GO in Europe, signaling strategic shifts ahead.

ReNerve Limited is scaling up its clinical trial for the NervAlign® Nerve Cuff following promising interim results that show significant pain reduction in nerve repair patients. The expanded study aims to solidify evidence for broader regulatory approval and market adoption.

DTI Group secures a major $2 million contract with Rio Tinto for autonomous locomotive tech and re-enters the European market through a new agreement with CAF.

Osteopore Limited reported a 7% year-on-year revenue increase in Q3 CY25, secured Swiss market approval for its implants, and saw a threefold sales surge through its Zimmer Biomet partnership.

Bioxyne Limited has reported a record-breaking first quarter for FY26, with revenues soaring 210% year-on-year, driven by strong demand in cannabis products and strategic European market advances.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.